Press Release (ePRNews.com) - HONG KONG - Nov 30, 2017 - Cedrus Investments (“Cedrus”), a global boutique investment firm, hosted the second meeting of the life sciences luncheon series for this year on Monday, 13th November 2017 in Shanghai at the St. Regis Shanghai Jingan. Mr. Randy Hice, Cedrus’ Chief Technical Officer and Member of the Life Sciences Advisory Board, shared with institutional investors, venture capitalists, and company executives his insights on two crucial themes in biotechnology: “New Frontiers in Immunology R&D” and “Increasing Laboratory Productivity and Meeting FDA Compliance through Software”.
Mr. Hice is recognized globally as a leading authority in laboratory informatics and the most published author in the world on topics of complex laboratory automation and workflow analysis. His recent positions included the CEO of Laboratory Expertise Center, Inc. and Manager of Global Strategy at Abbott Informatics, a division of Abbott Laboratories.
The event was well-received, and elicited high-level discussion in the Q&A session following Mr. Hice’s speech. Investors thought that it was especially important to understand the very latest developments in the biotech industry, as well as the overseas regulatory environment in order to conform to international conventions. Those attending the luncheon included executives from Fountainvest Partners, Franklin Templeton Sealand, Qiming VC, and SAIF Partners.
With its particular focus on the Greater China region, Cedrus has always positioned itself as a leader in fulfilling the needs of the investment community and companies around the world. Given our global network and expertise in the life sciences industry, we can serve as the platform for both investors and companies worldwide, facilitating both inbound and outbound investments for the Chinese and other geographical markets.
Cedrus’ Chief Technical Officer, Mr. Randy Hice said, “I am glad to be able to share the latest trends in immunology research and development with investors and companies, as well as providing some perspectives on how progressive scientific enterprises are utilizing the latest tools available to improve their data quality while achieving FDA compliance. The feedback from the event’s participants provided us with a better understanding of the active areas of interest from Chinese life sciences investors and companies, and that understanding will no doubt facilitate future cooperation regarding cross-border transactions and investment opportunities.”
Cedrus’ Chairman, Mr. Rani Jarkas said, “With its particular focus on the Greater China region, Cedrus has always positioned itself as a leader in fulfilling the needs of the investment community and companies around the world. Given our global network and expertise in the life sciences industry, we can serve as the platform for both investors and companies worldwide, facilitating both inbound and outbound investments for the Chinese and other geographical markets.”
About Cedrus Investments
Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.
For further information about Cedrus Investments, please visit www.cedrusinvestments.com.
Media Enquiry: Source :
Cedrus Investments Ltd.